Skip to main content
Premium Trial:

Request an Annual Quote

Lee Hartwell to Proteomics Scientists: The Biomarker Bottleneck Is in Discovery, Not Validation

BOSTON, March 13 (GenomeWeb News) - Proteomics researchers have not discovered enough cancer-related biomarkers, and they should modify and accelerate their research efforts if protein biomarker identification and validation are to have an impact in battling the disease, according to Nobel laureate Lee Hartwell.

 

Contrary to one theory that the problem with protein biomarkers lies in validating candidate biomarkers, Hartwell argued that validation and even approval are not the reasons why so few reliable protein biomarkers are known. "I put the problem squarely in discovery," he said yesterday during his talk at the second annual US HUPO meeting, held here this week. "We are not discovering markers effectively."

 

"Basic science has not had a big impact on cancer yet," said Hartwell, who is also president and director of the FredHutchinsonCancerResearchCenter. "There's an enormous opportunity ... for the whole proteomics industry and technologies to really have an impact on cancer."

 

He said in particular that improving molecular diagnostics will be the "most important thing" along that path.

 

Hartwell pointed out that while much scientific effort has gone into finding common SNPs that correlate to risk association for cancer, he believes protein biomarkers will be more effective in risk assessment, early detection, and cancer prevention. "Proteins are going to be even more informative" than the DNA-based diagnostics scientists use today, he said.

 

The discovery phase for biomarkers should be ramped up and multiplexed, he said. Whereas traditional drug discovery is limited to putting just one therapeutic in a patient or model organism at a time, a single serum or tissue sample from a patient can serve as a test for thousands of biomarkers at once, said Hartwell. Multiplexing in this way could make trials much more high-throughput and accelerate protein biomarker discovery, he said.

 

Hartwell also highlighted a need for efficient, low-cost assays to develop and validate candidate biomarkers. ELISA tests remain very expensive and time-consuming; scientists need highly sensitive assays that are far less costly and don't require them to develop two antibodies for each protein, he said. "I'm hopeful that within the next couple of years the bottleneck of assay development will not be limiting anymore."

 

One approach to dealing with this problem, and others related to proteomic technology, is working in very organized teams following the model laid out by the Human Genome Project, Hartwell said. Several such international biomarker-discovery teams already exist - he listed 11 in his talk - that have chosen to tackle a specific cancer. The teams, which are required to include expertise in mass spec, informatics, antibody development, clinical work, and mouse model research, are organized under HUPO. Anyone is welcome to form a team and take part. "I think the main value of participation is going to be learning from one another what works," Hartwell said.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.